Hillhouse Capital has led a US$230 million series B preferred stock financing in San Diego-based biopharmaceutical firm Gossamer Bio, according to the latter’s announcement. New investors participating in this financing include among others, a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA), Invus, The Baupost Group and Polaris Partners. Gossamer Bio’s existing investors, ARCH Venture Partners and Omega Funds, also meaningfully participated. Gossamer Bio is a San Diego-based biopharmaceutical company focused on discovering, developing, and commercializing immunology-based therapeutics in …

Hillhouse Capital Leads $230M Series B Preferred Stock Financing In US Biopharmaceutical Firm Gossamer Bio appeared first on China Money Network.